Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10

Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn’s disease

14-Oct-2011 - Shield Therapeutics announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).“Following our successful fundraising in June, we are delighted to have now ...

Shield Therapeutics Raises €8.2 million from Inventages Venture Capital via Series A Institutional Round

New investment to further fund the Phase III clinical programme of ST10-021 in Iron Deficiency Anaemia

06-Jun-2011 - Shield Therapeutics announced that it has successfully raised €8.2m (CHF10m/US$12m) from Inventages Venture Capital (Inventages) in its first institutional (Series A) financing round. "We are delighted to have successfully completed this fundraising which serves as further validation of the ...

Shield Therapeutics Appoints Richard Jones as Chief Financial Officer

18-May-2011 - Shield Therapeutics AG announced that it has appointed Richard Jones to the newly created role of Chief Financial Officer. Richard has more than 12 years of corporate finance and broking experience and was most recently Director and Head of Healthcare at Brewin Dolphin Investment Banking. During ...

Shield Signs Agreement for ST10-021 with AOP Orphan Pharmaceuticals

AOP Orphan to make strategic €3m investment in Shield Holdings

02-Nov-2010 - Shield Holdings AG announced that it has signed a strategic commercialisation agreement for its lead asset, ST10-021, an iron therapy product which has commenced Phase III clinical development, with AOP Orphan Pharmaceuticals AG (“AOP”). Under the terms of the agreement, Shield, whose products ...